N/A N=29 Feasibility of High Intensity Interval Training in Knee Osteoarthritis
Knee Osteoarthritis
Primary: Percent of Potential Participants Screened for the Study Who Are Enrolled — 19.3 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
Critical Limb Ischemia
Primary: Reintervention, Above Ankle Amputation and Restenosis (RAS) — 7; 4 Participants
Phase 4 N=36 ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence
HIV/AIDS
Primary: Hair Antiretroviral Imaging — 156.4826656; 1092.130868; 0.501209; 3942.692396 Signal Abundance (au)
Phase 4 N=112 Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy · Tractional Retinal Detachment
Primary: Best-corrected Visual Acuity — 1.25; 1.29; 1.16 LogMAR
N/A N=40 Telephone-linked Home-based Exercise Training in PD
Parkinson's Disease
Primary: Change in Hamilton Rating Scale for Depression (HAM-D) From Baseline to 6 Months — -1.4; 2.0 units on a scale — p=<0.05
Phase 3 N=1,212 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
Cervical Cancer · Vulvar Cancer · Vaginal Cancer
Primary: Anti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type — 787.8; 638.4; 598.7; 453.5 mMU/mL — p=< 0.001
Phase 2 N=60 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
Oropharyngeal Cancer
Primary: Percentage of Participants With Local Control — 97.9 percentage of patients
N/A N=5 Proton Radiotherapy for Stage I, IIA, and IIB Seminoma
Stage I, IIA and IIB Seminoma
Primary: Number of Serious Adverse Events — 0 Participants
Phase 3 N=123 Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs) in the Specified Categories Selected for Primary Endpoint Assessment — 58.5; 18.7; 12.2; 2.4…
Phase 3 N=160 Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.4 percentage of participants
Phase 3 N=126 Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
Relapsed and Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) After at Least 6 Cycles of Treatment Assessed by the Independent Review Committee — 35.8 percentage of participants
Phase 2 N=90 Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Summary of Best Modified Criteria Response Results, Bridged-to-Transplant (BTT) Participants, and Composite Remission Rates in Patients on Treatment With PLX3397 (Dose…
Phase 1 N=49 A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
Sarcoma, Soft Tissue
Primary: Pharmacokinetics (PK): Area Under The Concentration Curve Zero to Infinity (AUC[0-∞]) Doxorubicin — 2580; 2570; 2400; 2470 nanogram*hour/milliliter (ng*h/mL)
N/A N=150 Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study
Diabetes
Primary: Compare the Pearson Correlation of Glycated Albumin (GA) and Fructosamine Within All Subjects With the Performance Goal of 0.8 — 0.7056; 0.5271 Pearson correlation…
Phase 1 N=24 Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media
Acute Otitis Media
Primary: Number of Participants With Adverse Events — 2; 6 Participants